Covid-19 roundup: Study shows J&J's shot is much less effective against Delta variant; Novartis open to manufacturing other coronavirus vaccines — report
As the Delta variant rapidly spreads across the US — accounting for 83% of the country’s cases, CDC director Rochelle Walensky said yesterday — a new study shows the concerning strain renders Johnson & Johnson’s single-dose Covid-19 shot much less effective.
The study, which has not been peer-reviewed, showed that neutralizing titers induced by J&J’s vaccine decreased 5.4-fold against the “Delta plus” variant, a mutation that scientists say allows the virus to better attack the lungs. In comparison, titers induced by Pfizer/BioNTech’s candidate decreased by 2.7-fold against the Delta plus variant, and levels dropped 3.3-fold for Moderna’s candidate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
